clinical trial · NCT05198804
A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc·phase2·completed·n = 117
Ovarian CancerPlatinum-resistant Ovarian CancerPrimary Peritoneal CarcinomaFallopian Tube CancerAzenosertibNiraparib
brief summary
This is a Phase 1/2 study to evaluate the safety, clinical activity, pharmacokinetics (PK), and pharmacodynamics (PD) of ZN-c3 in combination with niraparib and of ZN-c3 Monotherapy in subjects with platinum-resistant ovarian cancer.
started
Jan 27, 2022
primary completion
Oct 15, 2025
completion
Jan 19, 2026
last updated
Mar 18, 2026
detailed description
This is a Phase 1/2 open-label, multicenter study to evaluate the safety, clinical activity, PK, and PD of ZN-c3 in combination with niraparib and of ZN-c3 Monotherapy in subjects with platinum-resistant ovarian cancer who have failed Poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance treatment.
official title
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination With Niraparib and ZN-c3 Monotherapy in Subjects With Platinum-Resistant Ovarian Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol